stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) EPS (diluted)
BioNTech SE Sponsored ADR's EPS (diluted) for fiscal 2025 was −$5.32, compared with −$3.00 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$6.85. Over the past ten years it has ranged from −$10.43 (fiscal 2017) to $46.89 (fiscal 2021); the current reading is higher than 22% of that period. EPS (diluted) has fallen for 4 consecutive fiscal years. BioNTech SE Sponsored ADR ranks 474th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$5.32 | — |
| FY2024 | −$3.00 | — |
| FY2023 | $4.15 | (89.57%) |
| FY2022 | $39.80 | (15.12%) |
| FY2021 | $46.89 | 66,885.71% |
| FY2020 | $0.07 | — |
| FY2019 | −$0.95 | — |
| FY2018 | −$0.30 | — |
| FY2017 | −$10.43 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.84 | — |
| Jun 2026 | −$3.77 | — |
| Mar 2026 | −$2.46 | — |
| Dec 2025 | −$1.46 | — |
| 24 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALNY Alnylam Pharmaceuticals, Inc. compare | $19.26 |
| ASND Ascendis Pharma A/S compare | $12.89 |
| EXEL Exelixis, Inc. compare | $3.34 |
| INCY Incyte Corporation compare | $1.88 |
| GMAB Genmab A/S Sponsored ADR compare | $1.27 |
| ROIV Roivant Sciences Ltd. compare | −$0.53 |
| INSM Insmed, Inc. compare | −$2.82 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| BNTX BioNTech SE Sponsored ADR | −$6.85 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BNTX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement